Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.

Cardiovascular drugs and therapy - 1 Jun 2015

Bryk Agata, Wypasek Ewa, Awsiuk Magdalena, Maj Dorota, Undas Anetta

Abstract excerpt

INTRODUCTION: Warfarin, a racemic mixture of S- and R-enantiomers, is the cornerstone of therapy in patients following cardiac valve replacement. S-warfarin is metabolized to 7-S-hydroxywarfarin by the cytochrome P450 isoform 2C9 encoded by CYP2C9 gene. R-warfarin is metabolized by multiple cytochromes P450. We sought to assess the impact of clinical and genetic factors on circulating warfarin metabolites...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Aortic Valve
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Metabolism, Inborn Errors

Share to Mitral Valve

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 25986145
DOI: 10.1007/s10557-015-6591-8

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors.PMID 25986145Read ↗

Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.Semantic proximity Read ↗

Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery.Semantic proximity Read ↗

The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement.Semantic proximity Read ↗

Integrated analysis of clinical and genetic factors on the interindividual variation of warfarin anticoagulation efficacy in clinical practice.Semantic proximity Read ↗

CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.Semantic proximity Read ↗

Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves: A Randomized Controlled Trial.Semantic proximity Read ↗

Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7-Hydroxy Warfarin in South Indian Patients.Semantic proximity Read ↗

Association Between Genetic Polymorphisms and Steady-State Plasma Concentration of Warfarin Optical IsomersSemantic proximity Read ↗

Genetic influence on bleeding and over-anticoagulation risk in patients undergoing warfarin treatment after heart valve replacements.Semantic proximity Read ↗

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.Semantic proximity Read ↗

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.Semantic proximity Read ↗

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.